Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE2V.L Regulatory News (E2V)

  • There is currently no data for E2V

Contract Win

20 Nov 2008 07:00

RNS Number : 5213I
e2v technologies PLC
20 November 2008
 



20 November  2008 

e2v technologies plc

Contract Win 

e2v technologies, a specialist developer and manufacturer of high technology components and sub-systems, announces an £11m contract renewal to supply Varian Medical Systems, Inc., headquartered in Palo Alto, US, with electron devices for incorporation into linear accelerators, for use in radiotherapy cancer treatment and cargo screening systems.

The contract will be worth at least £11m (payments will be in US dollars at the prevailing exchange rate) over two years, and is the first of a number of anticipated multi-year contract renewals for electron devices used in linear accelerators. e2v's products generate and deliver the microwave power required from the linear accelerator to produce X-rays used in both the imaging and radiation treatment of tumours as well as the imaging systems within cargo screening equipment.

This contract represents an increase in business with this customer, has the potential to increase in value over the term of the agreement, and is in line with management's growth expectations for this sector.

Keith Attwood, Chief Executive of e2v said: ``This multi-year contract renewal with Varian is a demonstration of the strong and close relationships we build with our strategic partners.''

For further information:

e2v technologies plc

Tel: +44 (0)1245 493493

Keith Attwood/Mike Hannant

www.e2v.com

Financial Dynamics

Tel: +44 (0)20 7269 7225

Jon Simmons/Sophie Kernon

   

NOTES FOR EDITORS

e2v 

e2v's objective is to be a global leader in the design and supply of specialised components and sub-systems that enable the world's leading systems companies to deliver innovative solutions for medical and science, aerospace and defence, and commercial and industrial markets.

e2v has 4 major product groups:

High performance electron devices and subsystems for applications including defence electronic countermeasures, radiotherapy cancer treatment, and radar systems

Advanced Imaging sensors and cameras for applications including industrial process control, dental X-ray systems, space science and life sciences

Specialist semiconductors, including logic, memory and microprocessors for high reliability mission-critical programs in avionics, defence and telecommunications, sensor data acquisition, and high speed data conversion

A range of professional sensing products for applications including fire, rescue and security thermal imaging, X-ray spectroscopy, and military surveillance, targeting and guidance

For the year ended 31 March 2008, e2v achieved sales of £205m and is listed on the London Stock Exchange. In October 2008 e2v acquired QP semiconductor, a leading US-based designer and supplier of specialty semiconductor components used in military and aerospace applications, establishing e2v's first US manufacturing base. 

The Company is headquartered in the United Kingdom and has approximately 1800 employees in six production facilities across Europe and North America. e2v also operates a global network of sales and technical support offices, supported by local distributors and resellers.

Further information is available from www.e2v.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTFKCKDABDDFDD
Date   Source Headline
26th Mar 20154:45 pmRNSHoldings in Company
19th Feb 201512:56 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
3rd Feb 20154:04 pmRNSTotal Voting Rights
30th Jan 20157:00 amRNSQuater three update
22nd Jan 20152:24 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
19th Jan 20152:55 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
8th Dec 20141:30 pmRNSTR-1: Notification of Major Interest in Shares
14th Nov 20143:27 pmRNSTR-1: Notification of Major Interest in Shares
11th Nov 20144:00 pmRNSTR-1: Notification of Major Interest in Shares
11th Nov 20143:43 pmRNSTR-1: Notification of Major Interest in Shares
11th Nov 20143:42 pmRNSTR-1: Notification of Major Interest in Shares
10th Nov 20144:07 pmRNSDirector/PDMR Shareholding - Replacement
10th Nov 20142:52 pmRNSDirector/PDMR Shareholding
10th Nov 20147:00 amRNSHalf Yearly Results
30th Oct 20148:38 amRNSTR-1: Notification of Major Interest in Shares
30th Oct 20148:35 amRNSTR-1: Notification of Major Interest in Shares
16th Oct 20147:00 amRNSPeriod End Update
22nd Sep 20143:37 pmRNSHolding(s) in Company
17th Sep 20148:39 amRNSNotice of Interim Results Announcement
15th Sep 201410:09 amRNSHolding(s) in Company
8th Sep 20142:17 pmRNSDirector/PDMR Shareholding
5th Sep 20143:34 pmRNSHolding(s) in Company
4th Sep 20142:53 pmRNSCompletion of acquisition
2nd Sep 20144:06 pmRNSTotal Voting Rights
8th Aug 201410:21 amRNSAwards under Long Term Incentive Plan
4th Aug 20142:36 pmRNSDirector/PDMR Shareholding
4th Aug 20141:45 pmRNSHolding(s) in Company
4th Aug 20147:08 amRNSAcquisition of AnaFocus
16th Jul 20149:56 amRNSResult of AGM
16th Jul 20147:00 amRNSInterim Management Statement
1st Jul 201412:18 pmRNSHolding(s) in Company
25th Jun 20143:02 pmRNSHolding(s) in Company
16th Jun 20144:20 pmRNSNotice of AGM
16th Jun 20144:15 pmRNSHolding(s) in Company
13th Jun 20141:25 pmRNSHolding(s) in Company
23rd May 20141:56 pmRNSHolding(s) in Company
19th May 20147:00 amRNSFinal Results
15th Apr 20147:00 amRNSTrading Statement
17th Mar 20144:47 pmRNSHolding(s) in Company
13th Mar 20143:08 pmRNSAwards under Share Incentive Plan
25th Feb 20147:00 amRNSChange of Director Details
21st Feb 20142:03 pmRNSHolding(s) in Company
3rd Feb 20145:00 pmRNSDirector/PDMR Shareholding
3rd Feb 20145:00 pmRNSDirector/PDMR Shareholding
3rd Feb 20145:00 pmRNSTotal Voting Rights
3rd Feb 20145:00 pmRNSTransaction in Own Shares
31st Jan 201412:10 pmRNSHolding(s) in Company
31st Jan 20147:00 amRNSInterim Management Statement
28th Jan 20147:00 amRNSDirector Declaration
28th Jan 20147:00 amRNSAppointment of Chief Executive - Start Date

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.